BIOMAT Database Logo BIOMAT Database Logo

Amplification refractory mutation system for prenatal diagnosis and carrier assessment in cystic fibrosis. 1989

C R Newton, and L E Heptinstall, and C Summers, and M Super, and M Schwarz, and R Anwar, and A Graham, and J C Smith, and A F Markham
ICI Diagnostics, Gadbrook Park, Northwich, Cheshire.

The amplification refractory mutation system (ARMS) has been applied to prenatal diagnosis and carrier detection of cystic fibrosis. The nucleotide sequence of both alleles of the PstI restriction fragment length polymorphism at the KM19 locus, which displays linkage disequilibrium with cystic fibrosis, has been determined. ARMS enables direct analysis of alleles of this polymorphism in DNA isolated from chorionic villus biopsy or white blood cells.

UI MeSH Term Description Entries
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010375 Pedigree The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition. Family Tree,Genealogical Tree,Genealogic Tree,Genetic Identity,Identity, Genetic,Family Trees,Genealogic Trees,Genealogical Trees,Genetic Identities,Identities, Genetic,Tree, Family,Tree, Genealogic,Tree, Genealogical,Trees, Family,Trees, Genealogic,Trees, Genealogical
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011296 Prenatal Diagnosis Determination of the nature of a pathological condition or disease in the postimplantation EMBRYO; FETUS; or pregnant female before birth. Diagnosis, Prenatal,Fetal Diagnosis,Fetal Imaging,Fetal Screening,Intrauterine Diagnosis,Antenatal Diagnosis,Antenatal Screening,Diagnosis, Antenatal,Diagnosis, Intrauterine,Prenatal Screening,Antenatal Diagnoses,Antenatal Screenings,Diagnosis, Fetal,Fetal Diagnoses,Fetal Imagings,Fetal Screenings,Imaging, Fetal,Intrauterine Diagnoses,Prenatal Diagnoses,Prenatal Screenings,Screening, Antenatal,Screening, Fetal,Screening, Prenatal
D012150 Polymorphism, Restriction Fragment Length Variation occurring within a species in the presence or length of DNA fragment generated by a specific endonuclease at a specific site in the genome. Such variations are generated by mutations that create or abolish recognition sites for these enzymes or change the length of the fragment. RFLP,Restriction Fragment Length Polymorphism,RFLPs,Restriction Fragment Length Polymorphisms
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females

Related Publications

C R Newton, and L E Heptinstall, and C Summers, and M Super, and M Schwarz, and R Anwar, and A Graham, and J C Smith, and A F Markham
The D1152H cystic fibrosis mutation in prenatal carrier screening, patients and prenatal diagnosis.
January 2011, Journal of medical screening,
C R Newton, and L E Heptinstall, and C Summers, and M Super, and M Schwarz, and R Anwar, and A Graham, and J C Smith, and A F Markham
Cystic fibrosis: prenatal diagnosis and carrier detection by DNA analysis.
August 1989, The Medical journal of Australia,
C R Newton, and L E Heptinstall, and C Summers, and M Super, and M Schwarz, and R Anwar, and A Graham, and J C Smith, and A F Markham
Mutation screening for prenatal and presymptomatic diagnosis: cystic fibrosis and haemochromatosis.
December 2000, European journal of pediatrics,
C R Newton, and L E Heptinstall, and C Summers, and M Super, and M Schwarz, and R Anwar, and A Graham, and J C Smith, and A F Markham
[Cystic fibrosis: linked DNA markers in prenatal diagnosis and carrier detection].
April 1988, Harefuah,
C R Newton, and L E Heptinstall, and C Summers, and M Super, and M Schwarz, and R Anwar, and A Graham, and J C Smith, and A F Markham
[Progress in the analysis of cystic fibrosis: prenatal diagnosis and carrier detection].
March 1989, Medicina clinica,
C R Newton, and L E Heptinstall, and C Summers, and M Super, and M Schwarz, and R Anwar, and A Graham, and J C Smith, and A F Markham
Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis.
February 1990, The New England journal of medicine,
C R Newton, and L E Heptinstall, and C Summers, and M Super, and M Schwarz, and R Anwar, and A Graham, and J C Smith, and A F Markham
Carrier screening for cystic fibrosis in a prenatal setting.
January 2001, Genetic testing,
C R Newton, and L E Heptinstall, and C Summers, and M Super, and M Schwarz, and R Anwar, and A Graham, and J C Smith, and A F Markham
Genetic analysis of cystic fibrosis in Denmark. Implications for genetic counselling, carrier diagnosis and prenatal diagnosis.
January 1992, Acta paediatrica (Oslo, Norway : 1992),
C R Newton, and L E Heptinstall, and C Summers, and M Super, and M Schwarz, and R Anwar, and A Graham, and J C Smith, and A F Markham
Cystic fibrosis: community knowledge and attitudes towards carrier screening and prenatal diagnosis.
April 1992, Clinical genetics,
C R Newton, and L E Heptinstall, and C Summers, and M Super, and M Schwarz, and R Anwar, and A Graham, and J C Smith, and A F Markham
[Cystic fibrosis. Prenatal diagnosis].
January 1991, Revista chilena de obstetricia y ginecologia,
Copied contents to your clipboard!